Capricor Therapeutics, Inc. (NASDAQ:CAPR) Receives Consensus Rating of “Hold” from Brokerages

Capricor Therapeutics, Inc. (NASDAQ:CAPR) has received an average rating of “Hold” from the twelve brokerages that are currently covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating and five have issued a buy rating on the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $30.25.

Several equities analysts have recently weighed in on the stock. HC Wainwright reiterated a “neutral” rating on shares of Capricor Therapeutics in a research note on Monday, July 27th. Piper Sandler upgraded shares of Capricor Therapeutics from a “neutral” rating to an “overweight” rating in a research report on Tuesday, September 1st. Maxim Group cut shares of Capricor Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, July 30th. Wall Street Zen downgraded shares of Capricor Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 1st. Finally, Cantor Fitzgerald upgraded shares of Capricor Therapeutics from a “neutral” rating to an “overweight” rating in a research note on Friday, August 14th.

Trending Headlines about Capricor Therapeutics

Here are the key news stories impacting Capricor Therapeutics this week:

• Positive Sentiment: Capricor will present 24-month HOPE-3 and open-label-extension data at the World Muscle Society Congress from September 29 to October 3. The presentations will include delayed-start and natural-history analyses submitted with a major amendment to the deramiocel biologics license application (BLA), providing a near-term opportunity for additional clinical visibility. The FDA’s target action date is November 22, 2026. Capricor to present HOPE-3 data at WMS 2026
• Neutral Sentiment: Brokerage coverage cited in recent reports assigns Capricor a consensus “Hold” rating, suggesting analysts are waiting for clearer regulatory and clinical developments before taking a more constructive view.
• Negative Sentiment: The FDA has extended its review of Capricor’s deramiocel BLA, increasing uncertainty over the timing and outcome of potential approval. The extension follows a major submission amendment and has intensified scrutiny of the application. FDA review extension and class-action deadline
• Negative Sentiment: Several law firms are promoting an ongoing securities class action covering investors who purchased CAPR shares primarily between December 17, 2025 and July 26, 2026. The complaints allege, among other issues, that Capricor’s Phase 3 HOPE-3 trial did not follow specified blinding and protocol procedures and that the final protocol differed from the statistical analysis plan. September 28, 2026 is the lead-plaintiff deadline. The announcements are allegations, not findings of liability, but they add litigation and reputational risk. Capricor class-action deadline alert

Insider Buying and Selling

In related news, CFO Anthony Bergmann sold 24,100 shares of Capricor Therapeutics stock in a transaction on Thursday, June 25th. The stock was sold at an average price of $30.38, for a total transaction of $732,158.00. Following the transaction, the chief financial officer directly owned 11,223 shares in the company, valued at approximately $340,954.74. The trade was a 68.23% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Over the last quarter, insiders sold 25,000 shares of company stock valued at $759,158. 9.20% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. Squarepoint Ops LLC increased its holdings in Capricor Therapeutics by 57.8% in the 2nd quarter. Squarepoint Ops LLC now owns 19,731 shares of the biotechnology company’s stock worth $475,000 after acquiring an additional 7,231 shares in the last quarter. Montanova Capital LLC lifted its holdings in Capricor Therapeutics by 7.2% during the second quarter. Montanova Capital LLC now owns 4,092,784 shares of the biotechnology company’s stock valued at $98,554,000 after purchasing an additional 274,184 shares in the last quarter. Bank of New York Mellon Corp bought a new position in shares of Capricor Therapeutics in the second quarter worth approximately $3,895,000. Glenmede Trust Co. NA increased its stake in shares of Capricor Therapeutics by 13.2% in the first quarter. Glenmede Trust Co. NA now owns 36,330 shares of the biotechnology company’s stock worth $1,104,000 after purchasing an additional 4,240 shares in the last quarter. Finally, Bank of America Corp DE increased its stake in shares of Capricor Therapeutics by 672.0% in the first quarter. Bank of America Corp DE now owns 415,483 shares of the biotechnology company’s stock worth $12,631,000 after purchasing an additional 361,664 shares in the last quarter. 21.68% of the stock is owned by hedge funds and other institutional investors.

Capricor Therapeutics Price Performance

Shares of CAPR opened at $9.07 on Friday. Capricor Therapeutics has a one year low of $2.96 and a one year high of $40.37. The firm has a market capitalization of $527.33 million, a P/E ratio of -3.70 and a beta of 0.72. The business has a fifty day moving average of $9.72 and a 200 day moving average of $22.54.

Capricor Therapeutics (NASDAQ:CAPR) last posted its earnings results on Thursday, August 13th. The biotechnology company reported ($0.70) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.11). Analysts expect that Capricor Therapeutics will post -1.71 EPS for the current fiscal year.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc is a biotechnology company focused on developing cell- and exosome-based therapies for serious diseases. The company’s programs are designed to use regenerative medicine and targeted delivery technologies to address conditions with limited treatment options.

Its leading therapeutic candidate is deramiocel, also known as CAP-1002, an allogeneic cell therapy derived from cardiosphere-derived cells. The program has been studied primarily for Duchenne muscular dystrophy, a genetic disorder that causes progressive muscle weakness and cardiac complications.